Literature DB >> 10155264

The burden of migraine. A review of cost to society.

R B Lipton1, W F Stewart, M Von Korff.   

Abstract

Migraine is a common episodic disorder with considerable impact on individuals and society. Migraine occurs with the highest prevalence between the ages of 25 and 55 years, potentially the most productive period of life. Severe migraine can lead to disruption of work, family and social life, the long term consequences of which may affect quality of life. The direct costs of migraine (due to medical care) are small compared with the indirect costs caused by absence from work and reduced productivity. Population-based studies are required to assess incidence, prevalence and distribution of the disease. These studies also reveal that migraine is currently underdiagnosed and undertreated. The cumulative impact of migraine on individuals produces the burden of illness on society. Measuring the severity of migraine is important in understanding the extent of the burden of migraine on the individual and on society. Measures of severity may be useful as predictors of disability and healthcare use. These measures may also be useful in assessing the need for patient care and treatment and help target those more disabled by migraine. Identifying and treating appropriate patients should reduce the impact of migraine on the individual and the burden of migraine on society.

Entities:  

Mesh:

Year:  1994        PMID: 10155264     DOI: 10.2165/00019053-199406030-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  24 in total

1.  Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis.

Authors:  R B Lipton; W F Stewart; D D Celentano; M L Reed
Journal:  Arch Intern Med       Date:  1992-06

2.  Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors.

Authors:  W F Stewart; R B Lipton; D D Celentano; M L Reed
Journal:  JAMA       Date:  1992-01-01       Impact factor: 56.272

3.  Healthcare resource and lost labour costs of migraine headache in the US.

Authors:  J T Osterhaus; D L Gutterman; J R Plachetka
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

4.  Migraine and psychopathology. Results of the Zurich cohort study of young adults.

Authors:  K R Merikangas; J Angst; H Isler
Journal:  Arch Gen Psychiatry       Date:  1990-09

5.  A nationwide survey of migraine in France: prevalence and clinical features in adults. GRIM.

Authors:  P Henry; P Michel; B Brochet; J F Dartigues; S Tison; R Salamon
Journal:  Cephalalgia       Date:  1992-08       Impact factor: 6.292

6.  Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults.

Authors:  N Breslau; G C Davis
Journal:  J Psychiatr Res       Date:  1993 Apr-Jun       Impact factor: 4.791

7.  Impact of migraine in the United States: data from the National Health Interview Survey.

Authors:  P E Stang; J T Osterhaus
Journal:  Headache       Date:  1993-01       Impact factor: 5.887

8.  Migraine, suicidal ideation, and suicide attempts.

Authors:  N Breslau
Journal:  Neurology       Date:  1992-02       Impact factor: 9.910

Review 9.  Migraine in the United States: a review of epidemiology and health care use.

Authors:  R B Lipton; W F Stewart
Journal:  Neurology       Date:  1993-06       Impact factor: 9.910

Review 10.  Migraine prevalence. A review of population-based studies.

Authors:  W F Stewart; A Shechter; B K Rasmussen
Journal:  Neurology       Date:  1994-06       Impact factor: 9.910

View more
  11 in total

Review 1.  WITHDRAWN: Dipyrone for acute primary headaches.

Authors:  Adriana S Ramacciotti; Bernardo G O Soares; Alvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2014-07-11

2.  Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.

Authors:  David W Dodick; Giorgio Sandrini; Paul Williams
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 3.  Diclofenac-potassium in migraine: a review.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 4.  Zolmitriptan: a review of its use in migraine.

Authors:  C M Spencer; N S Gunasekara; C Hills
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 5.  The economic burden of migraine to society.

Authors:  M D Ferrari
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

6.  The medical care utilization and costs associated with migraine headache.

Authors:  Jennifer Elston Lafata; Christina Moon; Carol Leotta; Ken Kolodner; Laila Poisson; Richard B Lipton
Journal:  J Gen Intern Med       Date:  2004-10       Impact factor: 5.128

7.  Adherence to headache treatment and profile of previous health professional seeking among patients with chronic headache: a retrospective analysis.

Authors:  Abouch Valenty Krymchantowski; Marcus Vinicius Adriano; Renemilda de Góes; Pedro Ferreira Moreira; Carla da Cunha Jevoux
Journal:  MedGenMed       Date:  2007-04-26

8.  Do over-the-counter medications for migraine hinder the physician?

Authors:  Thais Brown Tonore; Deborah S King; Sara L Noble
Journal:  Curr Pain Headache Rep       Date:  2002-04

Review 9.  Should butalbital-containing analgesics be banned? Yes.

Authors:  William B Young; Hua Chiang Siow
Journal:  Curr Pain Headache Rep       Date:  2002-04

Review 10.  Improving care through health economics analyses: cost of illness and headache.

Authors:  Francesco Saverio Mennini; Lara Gitto; Paolo Martelletti
Journal:  J Headache Pain       Date:  2008-07-05       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.